Yıl: 2022 Cilt: 12 Sayı: 1 Sayfa Aralığı: 91 - 96 Metin Dili: İngilizce DOI: 10.4274/buchd.galenos.2021.83713 İndeks Tarihi: 25-06-2022

Long-Term Effects of Nusinersen Combined Physiotherapy in Spinal Muscular Atrophy Type 1: A Case Study

Öz:
Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disorder that is characterized by generalized muscle weakness. Any study does not exist showing the results of Nusinersen and physiotherapy in SMA type 1. Our case was diagnosed with SMA type 1 at the age of 3 months. At 8 months of age, Nusinersen treatment and physiotherapy were started. The motor skills were evaluated with CHOP-Intend and Hammersmith Infant Neurological Examinations-2 (HINE-2) before physiotherapy and Nusinersen treatments, and also applied before each dose of Nusinersen during 22 months. An increase of 14 and 13 points in CHOP-Intend and HINE-2 were shown from baseline to the last visit, respectively. This report revealed the improvement of motor functions of a child with SMA type 1 by the combination of physiotherapy and Nusinersen. Our study may encourage physiotherapists and physicians to long-term use of a combination of these two therapies for the aim of motor improvement in this neuromuscular disease.
Anahtar Kelime:

Nusinersen ile Kombine Fizyoterapinin Spinal Musküler Atrofi Tip 1'de Uzun Dönem Etkisi: Olgu Çalışması

Öz:
Spinal musküler atrofi (SMA), genel kas zayıflığı ile karakterize otozomal resesif nöromüsküler bir hastalıktır. SMA tip 1'de Nusinersen ve fizyoterapinin sonuçlarını gösteren herhangi bir çalışma bulunmamaktadır. Olgumuza 3 aylıkken SMA tip 1 tanısı konuldu. Sekiz aylıkken, Nusinersen tedavisi ve fizyoterapi başladı. Motor becerileri, fizyoterapi ve Nusinersen tedavilerinden önce ve 22 ay boyunca da her Nusinersen dozundan önce CHOP-Intend ve Hammersmith Infant Neurological Examinations-2 (HINE-2) ile değerlendirildi. CHOP-Intend ve HINE-2’de ilk değerlendirmeden son değerlendirmeye sırasıyla 14 ve 13 puan artış gösterildi. Bu sonuç, SMA tip 1’li bir çocuğun motor fonksiyonlarının fizyoterapi ve Nusinersen kombinasyonu ile geliştiğini ortaya koydu. Çalışmamız, fizyoterapist ve hekimleri bu nöromusküler hastalıkta motor iyileştirme amacıyla bu iki tedavi kombinasyonunun uzun süreli kullanımına teşvik edebilir.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Olgu Sunumu Erişim Türü: Erişime Açık
  • 1. Lunn MR, Wang CH. Spinal muscular atrophy. Lancet. 2008;371(9630):2120-33. doi: 10.1016/S0140-6736(08)60921-6.
  • 2. D’Amico A, Mercuri E, Tiziano FD, Bertini E. Spinal muscular atrophy. Orphanet J Rare Dis. 2011;6(1):71. doi: 10.1186/1750-1172-6-71.
  • 3. Bertini E, Burghes A, Bushby K, Estournet-Mathiaud B, Finkel RS, Hughes RAC, et al. 134th ENMC International Workshop: Outcome Measures and Treatment of Spinal Muscular Atrophy11-13 February 2005Naarden, The Netherlands. Neuromuscul Disord. 2005;15(11):802-16. doi: 10.1016/j.nmd.2005.07.005.
  • 4. Mercuri E, Finkel RS, Muntoni F, Wirth B, Montes J, Main M, et al. Diagnosis and management of spinal muscular atrophy: part 1: recommendations for diagnosis, rehabilitation, orthopedic and nutritional care. Neuromuscul Disord. 2018;28(2):103-15. doi: 10.1016/j.nmd.2017.11.005.
  • 5. Mendell JR, Al-Zaidy S, Shell R, Arnold WD, Rodino-Klapac LR, Prior TW, et al. Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med. 2017;377(18):1713-22. doi: 10.1056/NEJMoa1706198.
  • 6. Wirth B, Brichta L, Schrank B, Lochmüller H, Blick S, Baasner A, et al. Mildly affected patients with spinal muscular atrophy are partially protected by an increased SMN2 copy number. Hum Genet. 2006;119(4):422-8. doi: 10.1007/s00439-006-0156-7.
  • 7. Chiriboga CA, Swoboda KJ, Darras BT, Iannaccone ST, Montes J, Darryl C, et al. Results from a phase 1 study of nusinersen (ISIS-SMNRx) in children with spinal muscular atrophy. Neurology. 2016;86(10):890-7. doi: 10.1212/WNL.0000000000002445.
  • 8. Finkel RS, Chiriboga CA, Vajsar J, Day JW, Montes J, De Vivo DC, et al. Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study. Lancet. 2016;388(10063):3017-26. doi: 10.1016/S0140-6736(16)31408-8.
  • 9. Wang CH, Finkel RS, Bertini ES, Schroth M, Simonds A, Wong B, et al. Consensus statement for standard of care in spinal muscular atrophy. J Child neurol. 2007;22(8):1027-49. doi: 10.1177/0883073807305788.
  • 10. Salem Y, Jaffee Gropack S. Aquatic therapy for a child with type III spinal muscular atrophy: a case report. Phys Occup Ther Pediatr. 2010;30(4):313-24. doi: 10.3109/01942638.2010.493097.
  • 11. Madsen KL, Hansen RS, Preisler N, Thøgersen F, Berthelsen MP, Vissing J. Training improves oxidative capacity, but not function, in spinal muscular atrophy type III. Muscle nerve. 2015;52(2):240-4. doi: 10.1002/mus.24527.
  • 12. Bulut N, Yardimci BN, Ayvat E, Aran OT, Yilmaz Ö, Karaduman A. The effect of two different aerobic training modalities in a child with spinal muscular atrophy type II: a case report. J Exerc Rehabil. 2019;15(2):322-6. doi: 10.12965/jer.1836604.302.
  • 13. Bora G, Subaşı-Yıldız Ş, Yeşbek-Kaymaz A, Bulut N, Alemdaroğlu İ, Tunca-Yılmaz Ö, et al. Effects of arm cycling exercise in spinal muscular atrophy type II patients: a pilot study. J Child neurol. 2018;33(3):209-15. doi: 10.1177/0883073817750500.
  • 14. Finkel RS, Mercuri E, Darras BT, Connolly AM, Kuntz NL, Kirschner J, et al. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med. 2017;377(18):1723-32. doi: 10.1056/NEJMoa1702752.
  • 15. Glanzman A, Mazzone E, Main M, Pelliccioni M, Wood J, Swoboda K, et al. The Children’s Hospital of Philadelphia infant test of neuromuscular disorders (CHOP INTEND): test development and reliability. Neuromuscul Disord. 2010;20(3):155-61. doi: 10.1016/j.nmd.2009.11.014.
  • 16. Bishop KM, Montes J, Finkel RS. Motor milestone assessment of infants with spinal muscular atrophy using the hammersmith infant neurological Exam-Part 2: Experience from a nusinersen clinical study. Muscle Nerve. 2018;57(1):142-6. doi: 10.1002/mus.25705.
  • 17. Kolb SJ, Coffey CS, Yankey JW, Krosschell K, Arnold WD, Rutkove SB, et al. Baseline results of the Neuro NEXT spinal muscular atrophy infant biomarker study. Ann Clin Transl Neurol. 2016;3(2):132-45. doi: 10.1002/acn3.283.
  • 18. Finkel RS, McDermott MP, Kaufmann P, Darras BT, Chung WK, Sproule DM, et al. Observational study of spinal muscular atrophy type I and implications for clinical trials. Neurology. 2014;83(9):810-7. doi: 10.1212/WNL.0000000000000741.
  • 19. Darras BT, Chiriboga CA, Iannaccone ST, Swoboda KJ, Montes J, Mignon L, et al. Nusinersen in later-onset spinal muscular atrophy: Long-term results from the phase 1/2 studies. Neurology. 2019;92(21):e2492-e506. doi: 10.1212/WNL.0000000000007527.
  • 20. Pechmann A, Langer T, Schorling D, Stein S, Vogt S, Schara U, et al. Evaluation of children with SMA type 1 under treatment with nusinersen within the expanded access program in Germany. J Neuromuscul Dis. 2018;5(2):135-43. doi: 10.3233/JND-180315.
  • 21. Lewelt A, Krosschell KJ, Stoddard GJ, Weng C, Xue M, Marcus RL, et al. Resistance strength training exercise in children with spinal muscular atrophy. Muscle Nerve. 2015;52(4):559-67. doi: 10.1002/mus.24568.
APA Aydın Yağcıoğlu G, Bulut N, Uğur F, ALEMDAROĞLU-GÜRBÜZ İ, Karaduman A, Yılmaz Ö (2022). Long-Term Effects of Nusinersen Combined Physiotherapy in Spinal Muscular Atrophy Type 1: A Case Study. , 91 - 96. 10.4274/buchd.galenos.2021.83713
Chicago Aydın Yağcıoğlu Güllü,Bulut Numan,Uğur Fatma,ALEMDAROĞLU-GÜRBÜZ İpek,Karaduman A. Ayşe,Yılmaz Öznur Long-Term Effects of Nusinersen Combined Physiotherapy in Spinal Muscular Atrophy Type 1: A Case Study. (2022): 91 - 96. 10.4274/buchd.galenos.2021.83713
MLA Aydın Yağcıoğlu Güllü,Bulut Numan,Uğur Fatma,ALEMDAROĞLU-GÜRBÜZ İpek,Karaduman A. Ayşe,Yılmaz Öznur Long-Term Effects of Nusinersen Combined Physiotherapy in Spinal Muscular Atrophy Type 1: A Case Study. , 2022, ss.91 - 96. 10.4274/buchd.galenos.2021.83713
AMA Aydın Yağcıoğlu G,Bulut N,Uğur F,ALEMDAROĞLU-GÜRBÜZ İ,Karaduman A,Yılmaz Ö Long-Term Effects of Nusinersen Combined Physiotherapy in Spinal Muscular Atrophy Type 1: A Case Study. . 2022; 91 - 96. 10.4274/buchd.galenos.2021.83713
Vancouver Aydın Yağcıoğlu G,Bulut N,Uğur F,ALEMDAROĞLU-GÜRBÜZ İ,Karaduman A,Yılmaz Ö Long-Term Effects of Nusinersen Combined Physiotherapy in Spinal Muscular Atrophy Type 1: A Case Study. . 2022; 91 - 96. 10.4274/buchd.galenos.2021.83713
IEEE Aydın Yağcıoğlu G,Bulut N,Uğur F,ALEMDAROĞLU-GÜRBÜZ İ,Karaduman A,Yılmaz Ö "Long-Term Effects of Nusinersen Combined Physiotherapy in Spinal Muscular Atrophy Type 1: A Case Study." , ss.91 - 96, 2022. 10.4274/buchd.galenos.2021.83713
ISNAD Aydın Yağcıoğlu, Güllü vd. "Long-Term Effects of Nusinersen Combined Physiotherapy in Spinal Muscular Atrophy Type 1: A Case Study". (2022), 91-96. https://doi.org/10.4274/buchd.galenos.2021.83713
APA Aydın Yağcıoğlu G, Bulut N, Uğur F, ALEMDAROĞLU-GÜRBÜZ İ, Karaduman A, Yılmaz Ö (2022). Long-Term Effects of Nusinersen Combined Physiotherapy in Spinal Muscular Atrophy Type 1: A Case Study. İzmir Dr. Behçet Uz Çocuk Hastanesi Dergisi, 12(1), 91 - 96. 10.4274/buchd.galenos.2021.83713
Chicago Aydın Yağcıoğlu Güllü,Bulut Numan,Uğur Fatma,ALEMDAROĞLU-GÜRBÜZ İpek,Karaduman A. Ayşe,Yılmaz Öznur Long-Term Effects of Nusinersen Combined Physiotherapy in Spinal Muscular Atrophy Type 1: A Case Study. İzmir Dr. Behçet Uz Çocuk Hastanesi Dergisi 12, no.1 (2022): 91 - 96. 10.4274/buchd.galenos.2021.83713
MLA Aydın Yağcıoğlu Güllü,Bulut Numan,Uğur Fatma,ALEMDAROĞLU-GÜRBÜZ İpek,Karaduman A. Ayşe,Yılmaz Öznur Long-Term Effects of Nusinersen Combined Physiotherapy in Spinal Muscular Atrophy Type 1: A Case Study. İzmir Dr. Behçet Uz Çocuk Hastanesi Dergisi, vol.12, no.1, 2022, ss.91 - 96. 10.4274/buchd.galenos.2021.83713
AMA Aydın Yağcıoğlu G,Bulut N,Uğur F,ALEMDAROĞLU-GÜRBÜZ İ,Karaduman A,Yılmaz Ö Long-Term Effects of Nusinersen Combined Physiotherapy in Spinal Muscular Atrophy Type 1: A Case Study. İzmir Dr. Behçet Uz Çocuk Hastanesi Dergisi. 2022; 12(1): 91 - 96. 10.4274/buchd.galenos.2021.83713
Vancouver Aydın Yağcıoğlu G,Bulut N,Uğur F,ALEMDAROĞLU-GÜRBÜZ İ,Karaduman A,Yılmaz Ö Long-Term Effects of Nusinersen Combined Physiotherapy in Spinal Muscular Atrophy Type 1: A Case Study. İzmir Dr. Behçet Uz Çocuk Hastanesi Dergisi. 2022; 12(1): 91 - 96. 10.4274/buchd.galenos.2021.83713
IEEE Aydın Yağcıoğlu G,Bulut N,Uğur F,ALEMDAROĞLU-GÜRBÜZ İ,Karaduman A,Yılmaz Ö "Long-Term Effects of Nusinersen Combined Physiotherapy in Spinal Muscular Atrophy Type 1: A Case Study." İzmir Dr. Behçet Uz Çocuk Hastanesi Dergisi, 12, ss.91 - 96, 2022. 10.4274/buchd.galenos.2021.83713
ISNAD Aydın Yağcıoğlu, Güllü vd. "Long-Term Effects of Nusinersen Combined Physiotherapy in Spinal Muscular Atrophy Type 1: A Case Study". İzmir Dr. Behçet Uz Çocuk Hastanesi Dergisi 12/1 (2022), 91-96. https://doi.org/10.4274/buchd.galenos.2021.83713